DCN Dx to Showcase New Technologies at NextGen Dx 2024
DCN Dx, a leading global provider of IVD CDMO and CRO services, announces its participation in the NextGen Dx Summit 2024, held from August 19-21 at the Walter E. Washington Convention Center in Washington, DC. Attendees are invited to visit DCN Dx at…
Vitamyna, the Leading Eco-Conscious Supplement Company With a #1 Focus on Purity and Value, Launches Innovative Personalized Daily Vitamin Pack Builder, Designed for Individual Health Needs and Goals, With Monthly Doorstep Delivery
As consumer demand for personalized health solutions rises, Vitamyna, a leading supplement company, launches its innovative Personal Pack Builder feature, revolutionizing how individuals address their nutritional and wellness needs. This technology allows customers to visit the vitamyna.com website and create…
LyGenesis Announces First Patient Dosed in its Phase 2a Clinical Trial of a First-in-Class Regenerative Cell Therapy for Patients with End-Stage Liver Disease
LyGenesis, a clinical-stage biotechnology company developing cell therapies for large unmet medical needs, announced today that the first patient has been dosed in their Phase 2a clinical trial evaluating their first-in-class allogenic regenerative cell therapy transplanted into patients’ lymph nodes…
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the results from the randomized controlled Phase II clinical trial, NIPU, are published in the European Journal of Cancer. The trial investigates the effect of…
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the first patient has been dosed in the PIVOT-006 Phase 3 clinical…
PCM Trials Acquires EmVenio Research to Create the Most Patient-Centric Model for Hybrid and Decentralized Clinical Trials
Denver-based PCM Trials, the largest independent mobile research nurse visit provider for decentralized clinical trials (DCTs), today announced the acquisition of EmVenio Research based in Durham, North Carolina. EmVenio is the largest provider of community-based clinical trial sites served with mobile research units. The…
New Guidance Published in The Lancet Recommends Early Intervention and Use of BIS to Reduce Impact of Arm Lymphedema on Breast Cancer Patients
ImpediMed, a pioneer in the field of medical technology, announced a significant advancement in the fight against breast cancer-related lymphedema, a common but often overlooked condition affecting breast cancer survivors. Leading medical journal eClinicalMedicine, part of The Lancet Discovery Science, recently…
Wasatch Biolabs Launches Proprietary Targeted DNA Methylation Sequencing Service for Researchers and Healthcare Providers
Wasatch Biolabs (WBL), a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies’ laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers. The technique is amplification and bisulfite conversion free, effectively bypassing the most…
Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress
Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today presented initial results from Phase 1 of its ongoing evaluation of HMB-001. A novel bispecific antibody, HMB-001 is in development as a prophylactic…
ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)
ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in a Phase I/II clinical trial for primary CNS tumors driven by MYC or MYCN amplifications. National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are…
